Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors — SGI-0470-02

Malignant Disease Clinical Trial

Official title:
Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens

Status Completed

Clinical Trial Summary

Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm.

Primary objective: Determine the MTD.

Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Malignant Disease

Clinical Trial Details

NCT number	NCT00881166
Study type	Interventional
Source	Astex Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	November 2007
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02447237` - Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients	N/A
Recruiting	`NCT05437328` - GD2/CD56 Bi-specific CAR-T Cell Therapy	Phase 1/Phase 2
Recruiting	`NCT03580109` - Spa Therapy for Upper or Lower Limb Lymphoedema	N/A
Active, not recruiting	`NCT03560882` - A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies	Phase 1
Terminated	`NCT03995927` - Palliative Radiation Oncology Chief's Clinic
Recruiting	`NCT02014506` - Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents	Phase 1/Phase 2